ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

DNAnexus Strengthens Leadership Team to Drive Ongoing Product Innovation and Commercial Growth

Company appoints healthcare technology industry veterans

Nupura Kolwalkar as chief product officer and Bill Madigan as chief commercial officer

DNAnexus, Inc., provider of the leading enterprise platform for precision health data, today announced the appointment of Nupura Kolwalkar as chief product officer and Bill Madigan as chief commercial officer. The two industry veterans bring decades of experience driving revenue growth and product innovation for leading healthcare technology companies.

“I’m pleased to welcome both Nupura and Bill to the DNAnexus leadership team. They are proven industry leaders with successful track records of managing cross-functional teams and scaling business operations for emerging healthcare software and data analytics providers,” said Thomas Laur, CEO at DNAnexus. “Their insights and expertise will help guide our long-term product and commercial strategies so that we can continue to make precision health a reality for all.”

Ms. Kolwalkar is highly regarded in the healthcare industry for her expertise in identifying and addressing unmet market needs through cutting-edge data, technology, and AI solutions. During the past 20 years, she has consistently guided organizations to conceptualize, develop, and deliver high-value products that deeply resonate with customers. Previously, she held executive positions at McKesson, Brightree, ResMed, Datavant, Sharecare, NextGen Healthcare Information Systems, and Pfizer. Ms. Kolwalkar holds a master of science degree in computer science from Auburn University and a master of arts degree in industrial statistics and econometrics from Savitribai Phule Pune University in India.

Mr. Madigan brings more than two decades of experience spanning product development, client services, sales, marketing, and channel-partner development in the healthcare and life sciences industries. Previously, he was the chief revenue officer at Komodo Health, an emerging AI-powered healthcare technology provider. Before that, he held several leadership roles across Optum’s healthcare and life sciences business units, including senior director for Optum Life Sciences and head of provider analytics. In these positions, he expanded the company’s collaborations with the top 20 global pharmaceutical companies and drove revenue growth in the provider analytics business. Mr. Madigan holds a master’s degree in business, technology, and finance from the D'Amore-McKim School of Business at Northeastern University.

“This is a great time to join DNAnexus as the company looks to strengthen its leadership position and enable more customers to accelerate scientific discovery, securely collaborate across the healthcare continuum, and, ultimately, unlock insights that improve patient lives,” said Mr. Madigan. “I look forward to working with this talented team and advancing efforts to scale commercial strategies and position the company for long-term growth.”

Today, DNAnexus has more than 45,000 registered users across 48 countries and actively manages more than 105 petabytes of complex clinical genomic, proteomic, and other multi-omic datasets on behalf of a growing network of collaborators. Its comprehensive enterprise platform for precision health data meets the most rigorous industry standards for data quality, security, privacy, and regulatory compliance.

About DNAnexus

DNAnexus, the enterprise platform for precision health data, is on a mission to accelerate the development, approval, and delivery of personalized treatments. Building on more than 15 years of bioinformatics innovation and genomics expertise, DNAnexus powers a connected data ecosystem trusted by the world’s precision health leaders. This flexible ecosystem makes omics and real-world data accessible, actionable, and secure while unlocking insights that improve patient lives. For more information, visit www.dnanexus.com or follow @DNAnexus on social media.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.05
+23.19 (10.41%)
AAPL  271.36
-0.04 (-0.01%)
AMD  253.99
-0.85 (-0.33%)
BAC  52.97
-0.06 (-0.11%)
GOOG  280.05
-1.85 (-0.65%)
META  651.68
-14.79 (-2.22%)
MSFT  517.03
-8.73 (-1.66%)
NVDA  202.43
-0.46 (-0.22%)
ORCL  259.39
+2.50 (0.98%)
TSLA  447.03
+6.93 (1.57%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.